Floatz logo

Infliximab

Hematopoietic and Lymphoid Cell Neoplasm

ECOG-ACRIN Cancer Research Groupmonoclonal_antibodyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

117 Active assets in the Hematopoietic and Lymphoid Cell Neoplasm cohort.

Asset / SponsorPhaseRating
Fludarabine
National Cancer Institute (NCI)
Phase 3BB
Pegloticase
M.D. Anderson Cancer Center
Phase 4BB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 2BB
Rasburicase
M.D. Anderson Cancer Center
Phase 4BB
METHOTREXATE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2BB

View all 50 →

Same molecule, other indications

Infliximab is also rated in:

CachexiaDormant
BB
Indicative ·
64 / 100
View asset →
hepatosplenic T-cell lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
colitisDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →